- Conditions
- VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
- Interventions
- JNJ-64179375 0.3 mg/kg, JNJ-64179375 0.6 mg/kg, JNJ-64179375 1.2 mg/kg, JNJ-64179375 (Dose to be Determined), JNJ-64179375 A mg/kg, JNJ-64179375 B mg/kg, JNJ-64179375 C mg/kg, JNJ-64179375 D mg/kg, Placebo JNJ-64179375, Apixaban placebo, Apixaban 2.5 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Interventions
- Apixaban 2.5 MG, Placebo oral tablet
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Atrial Fibrillation, Atrial Flutter
- Interventions
- warfarin, apixaban
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- Not listed
- Enrollment
- 20,976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 284
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more
- Conditions
- Acute Coronary Syndromes
- Interventions
- Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 4,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 143
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 125 more
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Rivaroxaban
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 22 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 9
- States / cities
- West Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,741 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 30
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Rosa, California + 27 more
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- Enoxaparin + Placebo, Apixaban + Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 17 more
- Conditions
- Cancer, VTE (Venous Thromboembolism)
- Interventions
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Venous Thrombosis
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 87
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 82 more
- Conditions
- Stroke, Atrial Fibrillation
- Interventions
- Non-vitamin K oral anticoagulant (NOAC)
- Drug
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 2,270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Atrial Fibrillation
- Interventions
- Apixaban, Acetylsalicylic acid
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 6,421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Tucson, Arizona • Anaheim, California + 62 more